CTVA vs AMGN

For growth investors, Amgen Inc.

(AMGN) is the stronger pick with 9. 9% revenue growth year-over-year, versus 2. 9% for Corteva, Inc. (CTVA). Amgen Inc. (AMGN) offers the better valuation at 23. 2x trailing P/E (14. 8x forward), making it the more compelling value choice. Analysts rate Corteva, Inc. (CTVA) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Amgen Inc.

(AMGN) is the cheapest at 23. 2x versus Corteva, Inc. at 52. 4x. On forward P/E, Amgen Inc. is actually cheaper at 14. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Corteva, Inc. wins at 1. 92x versus Amgen Inc. 's 5. 02x — a reasonable growth-adjusted valuation.

Over the past 5 years, Corteva, Inc.

(CTVA) delivered a total return of +82. 6%, compared to +49. 3% for Amgen Inc. (AMGN). Over 10 years, the gap is even starker: CTVA returned +203. 3% versus AMGN's +158. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Corteva, Inc.

(CTVA) is the lower-risk stock at 0. 29β versus Amgen Inc. 's 0. 60β — meaning AMGN is approximately 105% more volatile than CTVA relative to the S&P 500. On balance sheet safety, Corteva, Inc. (CTVA) carries a lower debt/equity ratio of 11% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Amgen Inc.

(AMGN) is pulling ahead at 9. 9% versus 2. 9% for Corteva, Inc. (CTVA). On earnings-per-share growth, the picture is similar: Amgen Inc. grew EPS 88. 2% year-over-year, compared to 23. 1% for Corteva, Inc.. Over a 3-year CAGR, AMGN leads at 11. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amgen Inc.

(AMGN) is the more profitable company, earning 21. 0% net margin versus 6. 3% for Corteva, Inc. — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMGN leads at 29. 1% versus 15. 1% for CTVA. At the gross margin level — before operating expenses — AMGN leads at 70. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Corteva, Inc. (CTVA) is the more undervalued stock at a PEG of 1. 92x versus Amgen Inc. 's 5. 02x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Amgen Inc. (AMGN) trades at 14. 8x forward P/E versus 22. 9x for Corteva, Inc. — 8. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AMGN: 6. 4% to $350. 76.

All stocks in this comparison pay dividends.

Amgen Inc. (AMGN) offers the highest yield at 2. 9%, versus 0. 8% for Corteva, Inc. (CTVA).

For long-horizon retirement investors, Corteva, Inc.

(CTVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 8% yield, +203. 3% 10Y return). Both have compounded well over 10 years (CTVA: +203. 3%, AMGN: +158. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CTVA (Basic Materials) and AMGN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.